All In Biotech

NDA 003444 · Esjay Pharma

Drisdol

Ergocalciferol · Oral · Provitamin D2 Compound

Last checked: Nov 20, 2026Latest source record: Nov 20, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1941

Jan 11, 1941

Approved uses

1

Original approval plus efficacy supplements

Registered trials

96

10 Phase 3, 2 recruiting

FAERS reports

29,734

24,323 serious, 4,036 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 4, 2026.

INDICATIONS AND USAGE Ergocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 11, 1941 Original approval
1 products under this application
  • DRISDOL · ERGOCALCIFEROL 50,000 IU · CAPSULE, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Ergocalciferol" as an intervention, any sponsor and status, largest first.

All 96 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,722
  • fatigue4,457
  • pain4,365
  • off label use4,267
  • dyspnoea4,230
  • nausea3,812
  • headache3,802
  • diarrhoea3,584
  • vomiting3,574
  • arthralgia3,442
  • condition aggravated3,340
  • drug hypersensitivity3,203

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004104
200595
200687
2007109
2008310
2009302
2010402
2011354
2012461
2013376
2014453
2015706
20161,165
20171,578
20181,671
20192,363
20202,511
20212,950
20223,298
20232,986
20243,276
20252,758
20261,417

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 158 on PubMed

Sponsor: Esjay Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.